{"organizations": [], "uuid": "7acc2857080561d80ef6415fcacf9253d349e8c7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 3}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180117.html", "section_title": "Archive News &amp; Video for Wednesday, 17 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-neurometrix-glaxosmithkline-announ/brief-neurometrix-glaxosmithkline-announce-collaboration-to-develop-quell-wearable-pain-relief-technology-idUSFWN1PC0YE", "country": "US", "domain_rank": 408, "title": "BRIEF-Neurometrix, Glaxosmithkline Announce Collaboration To Develop Quell Wearable Pain Relief Technology", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.999, "site_type": "news", "published": "2018-01-17T20:47:00.000+02:00", "replies_count": 0, "uuid": "7acc2857080561d80ef6415fcacf9253d349e8c7"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-neurometrix-glaxosmithkline-announ/brief-neurometrix-glaxosmithkline-announce-collaboration-to-develop-quell-wearable-pain-relief-technology-idUSFWN1PC0YE", "ord_in_thread": 0, "title": "BRIEF-Neurometrix, Glaxosmithkline Announce Collaboration To Develop Quell Wearable Pain Relief Technology", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "glaxosmithkline", "sentiment": "negative"}, {"name": "neurometrix", "sentiment": "negative"}, {"name": "glaxosmithkline consumer healthcare ltd", "sentiment": "negative"}, {"name": "neurometrix - co", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gsk", "sentiment": "none"}, {"name": "neurometrix inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 17 (Reuters) - Glaxosmithkline Consumer Healthcare Ltd :\n* NEUROMETRIX AND GLAXOSMITHKLINE CONSUMER HEALTHCARE ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP AND EXPAND ACCESS TO QUELL WEARABLE PAIN RELIEF TECHNOLOGY\n* NEUROMETRIX INC - GSK CONSUMER HEALTHCARE ACQUIRES EXCLUSIVE OWNERSHIP OF QUELL TECHNOLOGY FOR MARKETS OUTSIDE U.S.\n* NEUROMETRIX INC - NEUROMETRIX RETAINS EXCLUSIVE OWNERSHIP OF QUELL TECHNOLOGY IN U.S. MARKET.\n* NEUROMETRIX - CO, GSK CONSUMER HEALTHCARE TO CO-FUND DEVELOPMENT OF QUELL TECHNOLOGY FOR 3 YEARS BEGINNING IN 2018 THROUGH 2020\n* NEUROMETRIX - GSK CONSUMER HEALTHCARE TO PAY CO $5 MILLION FOR ASSETS RELATING TO QUELL TECHNOLOGY FOR MARKETS OUTSIDE U.S\n* NEUROMETRIX - GSK CONSUMER HEALTHCARE TO PAY CO UP TO $21.5M FOR QUELL UPON ACHIEVEMENT OF CERTAIN MILESTONES Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-17T20:47:00.000+02:00", "crawled": "2018-01-18T16:21:54.058+02:00", "highlightTitle": ""}